Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States

NCT02380274 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT02380274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02380274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Observational
Overall status
Completed
Start date
March 27, 2015
Completion date
January 14, 2021
Enrollment
1,030 (actual)
Sites
148

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, metastatic prostate cancer, prostate cancer